36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP

Key Points

• Blue Owl Capital Holdings LP purchased 36,259 Palvella Therapeutics shares valued at approximately $5.54 million, representing about 0.25% of the company and 0.8% of Blue Owl’s portfolio.
• Institutional ownership stands at 40.11%, with several investors adding or initiating positions. Analysts maintain a broadly positive outlook, assigning the stock an average “Buy” rating and a consensus price target of $209.14.
• PVLA shares opened at $142.58, near their 52-week high, but the company reported a quarterly EPS loss of $1.52, missing estimates of a $1.17 loss. COO Kathleen Goin also sold 4,302 shares under a pre-arranged Rule 10b5-1 plan.

Blue Owl Capital Holdings LP bought a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 36,259 shares of the company's stock, valued at approximately $5,541,000. Palvella Therapeutics comprises approximately 0.8% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 21st biggest holding. Blue Owl Capital Holdings LP owned approximately 0.25% of Palvella Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Palvella Therapeutics by 688.9% during the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company's stock valued at $2,232,000 after acquiring an additional 15,637 shares during the period. Jennison Associates LLC increased its holdings in shares of Palvella Therapeutics by 262.4% in the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company's stock worth $40,558,000 after acquiring an additional 280,573 shares during the period. Emerald Mutual Fund Advisers Trust bought a new stake in Palvella Therapeutics in the 1st quarter valued at about $13,190,000. WCM Investment Management LLC bought a new stake in Palvella Therapeutics in the 1st quarter valued at about $4,982,000. Finally, Profund Advisors LLC acquired a new position in Palvella Therapeutics during the 4th quarter valued at about $608,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. HC Wainwright reissued a "buy" rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital upgraded Palvella Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Stephens reiterated an "overweight" rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $209.14.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $142.58 on Friday. Palvella Therapeutics, Inc. has a 1 year low of $48.65 and a 1 year high of $161.38. The firm has a market cap of $2.05 billion, a P/E ratio of -29.52 and a beta of -0.17. The stock has a fifty day moving average price of $141.68 and a two-hundred day moving average price of $124.34.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, research analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $327,860.34. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source